Berenberg Bank Thinks Sensei Biotherapeutics’ Stock is Going to Recover

By Austin Angelo

Berenberg Bank analyst Zhiqiang Shu initiated coverage with a Buy rating on Sensei Biotherapeutics (SNSEResearch Report) today and set a price target of $27.00. The company’s shares closed last Friday at $16.50, close to its 52-week low of $15.45.

According to, Shu is a 3-star analyst with an average return of 10.0% and a 45.8% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Repare Therapeutics, and Arcus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sensei Biotherapeutics with a $29.33 average price target, representing a 73.9% upside. In a report released today, Piper Sandler also initiated coverage with a Buy rating on the stock with a $25.00 price target.

See today’s analyst top recommended stocks >>

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SNSE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.